Trial Profile
A randomized, open-label, crossover trial to evaluate methylphenidate hydrochloride extended-release chewable tablet versus methylphenidate hydrochloride immediate-release chewable tablets in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2016
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Tris Pharma
- 06 Apr 2016 New trial record
- 24 Mar 2016 Pharmacokinetic analysis (n=31) published in the Clinical Therapeutics.